Glucagon Receptor Protein-VLP (GCGR)
-
- Target Alle Glucagon Receptor (GCGR) Proteine anzeigen
- Glucagon Receptor (GCGR)
- Protein-Typ
- VLP
-
Spezies
- Human
-
Quelle
- HEK-293 Cells
- Verwendungszweck
- Human GCGR / Glucagon receptor Full Length Protein (VLP)
- Sequenz
- Ala 26 - Asn 432
- Produktmerkmale
- Human GCGR Full Length Protein (VLP) is expressed from human 293 cells (HEK293). It contains AA Ala 26 - Asn 432 (Accession # P47871-1).
- Endotoxin-Niveau
- 1.0 EU per μg
- Top Product
- Discover our top product GCGR Protein
-
Glucagon Receptor (GCGR) (AA 27-137) protein (His tag)
Crystallography grade GCGR Spezies: Maus Wirt: Insektenzellen Recombinant >95 % as determined by SDS PAGE, Size Exclusion Chromatography and Western Blot. Crys, ELISA, SDS, WB
Glucagon Receptor (GCGR) (AA 26-477) protein (rho-1D4 tag)Crystallography grade GCGR Spezies: Human Wirt: Insektenzellen Recombinant >95 % as determined by SDS PAGE, Size Exclusion Chromatography and Western Blot. Crys, ELISA, SDS, WB
Glucagon Receptor (GCGR) (AA 27-485) protein (rho-1D4 tag)Crystallography grade GCGR Spezies: Maus Wirt: Insektenzellen Recombinant >95 % as determined by SDS PAGE, Size Exclusion Chromatography and Western Blot. Crys, ELISA, SDS, WB
Glucagon Receptor (GCGR) (AA 26-136) protein (His tag)GCGR Spezies: Human Wirt: HEK-293 Cells Recombinant >90 % as determined by SDS-PAGE.
-
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Liquid
- Buffer
- PBS, Arginine, pH 7.4
- Lagerung
- -80 °C
- Informationen zur Lagerung
- -70°C
-
- Target
- Glucagon Receptor (GCGR)
- Andere Bezeichnung
- GCGR (GCGR Produkte)
- Synonyme
- GCGR Protein, GGR Protein, GR Protein, glucagon receptor Protein, GCGR Protein, Gcgr Protein
- Hintergrund
- The protein encoded by this gene is a glucagon receptor that is important in controlling blood glucose levels. Defects in this gene are a cause of type 2 diabetes mellitus (T2DM) . The ever increasing prevalence of type 2 diabetes mellitus in the developed and developing nations calls for the introduction of new and more effective treatments. Glucagon receptor (GCGR) antagonists are highly validated in preclinical models of T2DM and thus have the potential to be developed as a new therapy.
- Pathways
- Carbohydrate Homeostasis, Regulation of Carbohydrate Metabolic Process
-
